-
-
-
-
-
-
-
Senti Bio reports Q3 financial results, confirms ASH data presentation
-
-
-
-
-
-
-
Senti Biosciences' (SNTI) SENTI-202 Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
-
-
-
-
-
-
-
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights
-
-
-
-
-
-
-
Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights
-
-
-
-
1,197,344 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

